Συγγραφείς:
Terpos, E.
Gavriatopoulou, M.
Ntanasis-Stathopoulos, I.
Briasoulis, A.
Gumeni, S.
Malandrakis, P.
Papanagnou, E.-D.
Migkou, M.
Kanellias, N.
Kastritis, E.
Trougakos, I.P.
Dimopoulos, M.A.
Λέξεις-κλειδιά:
bnt 162b 2; immunological antineoplastic agent; immunomodulating agent; lenalidomide; neutralizing antibody; proteasome inhibitor; tozinameran, adult; aged; antibody production; antibody response; antibody titer; cancer immunotherapy; controlled study; coronavirus disease 2019; female; human; humoral immunity; Letter; major clinical study; male; multiple myeloma; repeated drug dose; Severe acute respiratory syndrome coronavirus 2; vaccination
